Strong Top-Line Growth
Net revenue of $16.7M in Q1 2026, up 65% year-over-year and 16% sequentially, driven by new surgeon adoption, increased utilization and higher ASPs.
Raised Full-Year Guidance
Full-year 2026 net revenue guidance increased to $65M–$68M, representing growth of 37%–44% versus 2025 (prior guide $62M–$65M, or 31%–37%).
High and Improving Gross Margins
Reported gross margin of 77.7% in Q1 2026 versus 76.9% in the prior year; management expects similar margins for the balance of 2026 with further improvement potential from cost-down programs.
Large Volume and Surgeon Adoption Gains
Total implant volume of 2,184 units in Q1, up 51% year-over-year; core and contender surgeon count was 134 at end of 2025 (up 61% YoY); the company more than doubled the number of new customers entering its funnel versus Q1 2025.
Commercial / Educational Momentum
44 SI-sponsored educational events in Q1; 2026 Napa symposium attendance up >70% year-over-year and >70% of non-customer attendees have already performed or committed to first/increased cases shortly after the meeting.
Product and Technology Milestones
I-135RFX humeral stem moved from limited release to full commercial launch with expanded fracture indications; initiated limited release of N22 Glenosphere; >500 patients enrolled in clinical registry; micro-robotic partnership progressing faster than expected with 510(k) targeted in 2027.
Strong Cash Position and Proactive Fulfillment
Cash and cash equivalents of $108.5M as of March 31, 2026; proactively increased inventory and asset purchases to support accelerated growth and avoid supply constraints; management expects materially lower cash burn beginning in Q2.